Cutis
-
Clinical Trial
Antipruritic hydrogel for the treatment of atopic dermatitis: an open-label pilot study.
Atopic dermatitis (AD) is the most common chronic inflammatory skin disease in industrialized nations. The efficacy and tolerability of Atrapro (RD047-26) antipruritic hydrogel was evaluated in 17 adult participants with mild to moderate AD with associated pruritus. The antipruritic hydrogel was applied 3 times daily to the affected areas of the body, and participants were evaluated on days 3, 7, and 14 (end of study). ⋯ Most participants (82% [14/17]) experienced relief from itching by day 3, and this improvement remained consistent at each of the follow-up office visits. The only adverse event (AE) was mild postapplication skin dryness, which was reported by 59% (10/17) of participants and resolved with increased use of emollients. Based on these promising results, further research on the antipruritic hydrogel is warranted.
-
Case Reports
Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
The most common cutaneous side effects to epidermal growth factor receptor (EGFR) inhibitors are follicular or acneiform eruptions, nail disorders, xerosis, and desquamation. Although topical and oral antibiotics with or without topical corticosteroids usually are safe and effective treatment options for acneiform eruptions due to EGFR inhibitors, they are not always successful in refractory cases. ⋯ Complete response was observed in all 3 patients. We recommend oral isotretinoin for the management of acneiform reactions to EGFR inhibitors when the lesions persist or worsen despite antibiotic treatment.
-
We report a case of a 22-year-old female with an asymptomatic telangiectatic rash involving her left breast of 10 years' duration. Biopsies revealed cularis findings consistent with telangiectasia m a eruptiva perstans (TMEP). Telangiectasia macularis eruptiva perstans most often presents in a symmetric fashion; our patient represents an unusual case of unilateral TMEP involving the breast. Therefore, TMEP should be considered when a patient presents with telangiectasia, even if the presentation is unilateral.
-
Case Reports
A case of argyria: multiple forms of silver ingestion in a patient with comorbid schizoaffective disorder.
Argyria is a rare cutaneous manifestation of silver deposits in the skin, characterized by a grayish blue discoloration, particularly in sun-exposed areas. We report the case of a patient with a history of schizoaffective disorder and type 2 diabetes mellitus who presented with argyria of the face and neck. The patient had a history of ingesting colloidal silver proteins (CSPs) for approximately 10 years as a self-prescribed remedy for his medical conditions. ⋯ Argyria is the most predominant manifestation of silver toxicity. It is unclear if our patient began taking CSP because of his schizoaffective disorder or if silver toxicity may have induced somatic delusions; however, it is important for physicians to have a thorough understanding of alternative therapies on the market. We present a detailed background on silver ingestion and its systemic effects.